[3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemifumarate) is a MEK inhibitor currently being tested in multiple combinations, including a completed phase 3 clinical trial in combination with vemurafenib, in patients with metastatic melanoma (Larkin et al., 2014) . The pharmacokinetics of cobimetinib has been well characterized in clinical pharmacology studies in healthy subjects (Musib et al., 2013) . Cobimetinib undergoes low clearance (11.7 L/h), is well absorbed (F a ~88%; estimated from the sum of radioactivity recovered in urine (17.8%) and radioactivity in feces that was characterized as metabolites (69.9%) and has an absolute bioavailability of 45% (Musib et al., 2013) .
Clinical data from the absolute bioavailability study suggests that intestinal first pass metabolism may play a role in decreasing the bioavailability of cobimetinib. Indeed, analysis of the data from the absolute bioavailablity study with knowledge of F a ,
The differences in metabolizing enzyme specificity and regulation, limit the use of animal models in directly predicting metabolism/disposition in humans (Martignoni et al., 2006) . The increasing availability of "knockout-knockin" mice, where the specific mouse gene is replaced with the corresponding human gene of interest has provided the opportunity to interrogate in an in vivo setting, for example, the ability to predict a priori the role of transporters/CYP's on a drug/compounds disposition (Scheer et al., 2008; Scheer et al., 2010; Scheer et al., 2012) . Specifically, the generation of the CYP3A4 knockout and humanized CYP3A4 mice with differential expression of CYP3A4 in the intestine or liver or in both the intestine or liver provide an attractive tool to investigate the contribution of each organ to a compounds/drug disposition. For example, van Herwaarden et al., 2007 (van Herwaarden et al., 2007 , have shown using these mice the contribution of intestinal first pass metabolism and/or P-gp efflux on the disposition of docetaxel. In addition, van Waterschoot, et al., 2009 (van Waterschoot et al., 2009a 
Determining Contribution of Intestinal and Hepatic CYP3A4 in Mice
Animals (n=3 female mice for transgenic group; n=6 female for FVB group) were dosed with cobimetinib 1 mg/kg IV (in phosphate buffered saline) or 5 mg/kg orally (suspended in 0.5% methylcellulose/0.2% Tween (MCT)). In addition to PK analysis, terminal plasma samples were collected from n=2 animals after IV and PO dosing for metabolite determination at 1 and 3 h post cobimetinib dosing. 
Effect of CYP3A4 Inhibition or Induction on Cobimetinib Exposure in Mice

LC-MS/MS Analysis
Concentrations of cobimetinib were determined by a non-validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. The plasma samples were prepared for analysis by placing a 25 µL aliquot into a 96-well plate followed by the addition of 5 µL of internal standard ( 6 C 13 analogue of cobimetinib, 2µg/mL in 50:50, v:v, DMSO:water) and 200 µL acetonitrile. The samples were vortexed and centrifuged at 1600 g for 15 min at room temperature, 50µL of the supernatant was diluted with 150 µL of water and 5 µL of the solution was injected onto an analytical column. A SIL-30ACMP autosampler system (Shimadzu, Columbia MD) was linked to LC-30AD pumps (Shimadzu, Columbia MD), coupled with an API 5500 Qtrap mass spectrometer (AB Sciex, Foster City, CA) for sample analysis. The aqueous mobile phase was water with 0.1% formic acid (A) and the organic mobile phase was acetonitrile with 0.1% formic acid (B). The gradient was as follows: starting at 25% B and increased to 95% B for 0.6 min, maintained at 95% B for 0.1 min, then decreased to 25% B within 0.1 min.
The total flow rate was 1.4 mL/min and samples were injected onto a Kinetex XB C-18
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Pharmacokinetic Analysis
Pharmacokinetic (PK) parameters were calculated by non-compartmental methods as described in Gibaldi and Perrier (Gibaldi and Perrier, 1982) using Phoenix™ WinNonlin ® , version 6.3.0 (Pharsight Corporation, Mountain View, CA) All PK parameters are presented as mean ± standard deviation (SD).
In vitro Metabolism Studies
Pooled human liver microsomes were obtained from BD Gentest (San Jose, CA; catalog #452117). Liver microsomes from FVB, Cyp3a -/-or Cyp3a -/-Tg-3A4 Hep/Int mice were freshly prepared from individual livers using a modification of the method described by
Hill (Hill, 2004) . Briefly, tissues were homogenized in 4 volumes of homogenization buffer using an Omni Bead Ruptor 24 (Omni International, Kennesaw, GA). clearance in the units of µL/min/mg microsomal protein was calculated utilizing the in vitro half-life approach described by Obach et al. (Obach et al., 1997) . Scaling to whole body CL were conducted using the "well stirred" model described by Wilkinson and Shand (Wilkinson and Shand, 1975) and previously reported physiological parameters for mouse and human (Davies and Morris, 1993) .
Metabolite Confirmation
Three previously identified circulating human oxidative metabolites of cobimetinib (Takahashi et., al., manuscript in preparation) were monitored by LC-MS/MS (M12, M18 and M19; see supplementary Figure S1 ). Plasma collected at 1 and 3 h post cobimetinib dosing from transgenic mice were extracted with acetonitrile and the supernatants were concentrated under vacuum and injected to the LC column. Cobimetinib and its metabolites were eluted from a Kinetex PFP 50×2.1 mm, 2.6 µm column (Phenomenex, Torrance, CA) with mobile phases of 0.1% formic acid in water and acetonitrile.
Metabolites were measured using multiple reaction monitoring (MRM) with a 5500
QTrap equipped with a TurboIonSpray interface (AB Sciex, Foster City, CA (van Waterschoot et al., 2009a) where intestinal CYP3A4 had a major impact on oral exposure of these drugs (7.5-and 2-fold lower AUC in mice with intestine only vs. liver only expression of CYP3A4, for docetaxel and triazolam, respectively).
In Cyp3a -/-Tg-3A4 Hep/Int mice, the fraction escaping intestinal extraction (F g ) was estimated to be 0.23; where F = Fa*Fg*Fh (F = 0.14, F h = 0.61 and F a was assumed to be This article has not been copyedited and formatted. The final version may differ from this version. (Austin et al., 2002) ) the in vivo CL observed in the respective mice (Table   1 ). These in vitro data infers that the 9-fold difference of PO exposure in WT, Cyp3a
-/-and Cyp3a -/-Tg-3A4 Hep/Int transgenic mice are likely to be from intestinal metabolism (Table 1) and not from hepatic CL.
Recently, the use of CYP3A4 transgenic mice to predict the CL of CYP3A4 substrates in human had been reported (Mitsui et al., 2014) . Using 6 CYP3A4 substrates, the in vitro intrinsic CL from human and CYP3A4 transgenic mouse liver microsomes were reported This article has not been copyedited and formatted. The final version may differ from this version. (Mitsui et al., 2014) . Thus, a priori, a regression would have to be established for model compounds before human CL predictions could be made using data from transgenic mice. Although not discussed by the authors, it is worth noting, that hepatic extraction, derived from transgenic mouse and human were within 2-fold. It appears at this point that the direct utility of using transgenic mice in predicting human CL remains unclear.
To verify the relevance of the CYP3A4 transgenic mouse model we sought to determine if the circulating oxidative metabolites of cobimetinib (albeit minor; each <5% of total radioactivty in plasma, Takahashi et., al., Manuscript in preparation) in human were also observed in the transgenic mice. Indeed in the CYP3A4 transgenic mice, oxidative metabolites observed in human circulation (M12, M18, M19) were observed (see Supplemental Figure S1 -A for structures). This provided supportive information that the metabolic pathways in the transgenic mice reflected those in human (which was CYP3A4 mediated; Ryan Takahashi, manuscript in preparation). M12 and M19 were also observed in plasma of FVB and Cyp3a(-/-) mice (see Supplemental Figure S1 -B), the presence of human metabolites in the FVB and Cyp3a(-/-) mice was not unexpected per se as mouse Collectively, this data suggest that the transgenic mice provide a unique metabolite profile (compared to WT and Cyp3a(-/-)), representative (at least qualitatively) of human metabolites (see Supplemental Figure S1 ).
To further assess the utility of the transgenic mice, DDI studies were conducted in Cyp3a (Table 2 ). In addition, IV administration of cobimetinib with itraconazole (oral) resulted in ~4-fold increase in cobimetinib AUC and half-life, this is in keeping with a similar magnitude decrease in CL ( Table 2 ). The greater DDI effect (~8-vs. ~4-fold) observed after oral dosing of cobimetinib was consistent with the contribution of intestinal CYP3A4 to the CL of cobimetinib. This finding was similar to the clinical observation reported where a greater DDI effect was observed after oral vs. IV administration of midazolam with the CYP3A inhibitor clarithromycin. A 7-and 2.7-fold increase in the exposure (AUC) of midazolam were observed after oral and IV administration, respectively (Gorski et al., 1998 ).
Itraconazole did not significantly alter the exposure of cobimetinib in Cyp3a KO animals, suggesting that in mice only the Cyp3a isoenzyme was inhibited by itraconazole (Table   This article 3). In addition, itraconazole co-administration to FVB (WT) mice resulted in a 5.8-fold increase in oral exposure of cobimetinib (within the range of fold increase observed in transgenic mice; Table 3 ). This is consistent with the suggestion that Cyp3a enzymes in mice may be the primary enzyme that metabolizes cobimetinib (Table 3) . Collectively this data suggests that the magnitude increase in CL of cobimetinib from coadministration with itraconazole to Cyp3a -/-Tg-3A4 Hep/Int mice was higher than expected based on the apparent low CYP3A4 contribution to CL of cobimetinib (~ 30% difference in CL between Cyp3a(-/-) vs. transgenic animals; Table 1 ) and the specificity of itraconazole to inhibition of only Cyp3a. The reason for the higher than expected decrease in cobimetinib CL when co-administered with itraconazole is unclear. Of note, systemic exposure of itraconazole in this studies was similar to clinical exposures from a dose of 200 mg Sopranox R solution (Sopranox R Product Insert and Supplemental Figure   S2 ), however the intestinal/hepatic exposures of itraconazole are unknown and may be higher than clinical tissue exposures based on the higher mg/kg dose.
In addition to studying the effect of CYP3A4 inhibition, using the PXR-CAR-CYP3A4/3A7 mice the effect of induction was investigated. It has been reported that the PXR-CAR-CYP3A4/3A7 model displays human-like CYP3A4 induction to various PXR inducers (Hasegawa et al., 2011) . In addition to an increase in CYP3A4 mRNA levels after rifampin induction in PXR-CAR-CYP3A4/3A7 mice, in vivo exposures of triazolam were reported to be decreased by up to 90% after rifampin treatment (Table 2) . As a reference, clinical induction of CYP3A from 600 mg of rifampin has been reported to decrease the exposure of the prototypical CYP3A substrate, midazolam by ~90-98% (Backman et al., 1996; Gorski et al., 2003) ; (University of Washington Drug Interaction Database). Thus, the observed effect of rifampin induction on cobimetinib in PXR-CAR-CYP3A4/3A7 mice was on the lower end of the scale compared to a sensitive CYP3A4 substrate such as midazolam. Worth noting, the exposure of rifampin in this study was consistent with clinical concentrations observed from a dose of 600 mg (Kwara et al., 2014) ; (see Supplementary Figure S2 ).
The utility of a specific transgenic model is dependent on the disposition and metabolism of the compound/drug of interest. For instance, since cobimetinib was predominantly metabolized by CYP3A4, and was metabolized by both intestinal and liver CYP3A, the CYP3A4 transgenic mice with differential expression in each tissue was an ideal model.
It appeared that unlike midazolam, where mice Cyp2c metabolized midazolam and confounded the interpretation of data from Cyp3a KO mice (van Waterschoot et al., 2008) , cobimetinib disposition and metabolism appeared to be mainly driven by Cyp3a/CYP3A in mice and human. However, some contribution from CYP (as evidenced by the Cyp3a KO data) and nonCYP enzymes such as UGT (fm likely to be low) on the metabolism of cobimetinib cannot be excluded. One consideration when using this model is that for some CYP3A substrates, the contribution of CYP3A5 to the metabolism of a compound can be substantial (Lamba et al., 2002) . While cobimetinib appears to be mainly metabolized by CYP3A4 (data on file), for midazolam, vincristine and atanazavir, CYP3A5 has been reported to contribute to ~50-80% to the overall f m 
TABLES
